Mirror Daily

Sunday, April 11, 2021
Log in
  • Home
  • National & Global News
  • Business & Economy
  • Tech & Science
  • Health
  • About Mirror Daily
    • Our Team
    • Contact Us
    • Terms of Use
    • Privacy Policy GDPR
  • Latest News
    • The Geological Features of Pluto Have Just Gotten Dark Names Inspired from the Underworld
    • The Abuse of Imodium
    • McDonald’s Salads are worse than their Burgers
    • US Family Sues Hospital Over Botched Tonsillectomy
    • Should We Go Back to The Moon?
    • Photo of Gay Military Men Kissing Goes Viral

Pages

  • About Mirror Daily
  • Contact Us
  • Fossil Reveals That Dinosaurs Suffered from Arthritis
  • Our Team
  • Privacy Policy GDPR
  • Terms of Use
  • World Breastfeeding Week: Advantages and Disadvantages

Recent Posts

  • Canadian Teen Killed by Toxic Shock Syndrome on School Trip June 29, 2018
  • Donut Fries Coming to Dunkin’ Donuts Nationwide June 28, 2018
  • Kohl’s Hiring Workers for Holiday Season amid Labor Shortage June 28, 2018
  • This is How You’re Sabotaging Your Skin Safety June 27, 2018
  • SF Woman Calls Cops on Little Girl for Selling Water on Street June 26, 2018
  • Sarah Sanders Misused Official Twitter Account to Complain about Restaurant June 25, 2018
  • Man Arrested for Placing 10-Ft-Long Heroin Spoon Outside Drug Maker HQ June 25, 2018

Eylea is Preferred for Diabetes-Related Vision Loss

February 19, 2015 By Melissa Gansler Leave a Comment

The diabetic macular edema (DME) drug Eylea (aflibercept) was proved to provide greater visual improvement than Avastin (bevacizumab) or Lucentis (ranibizumab), a recent study found. This applies to a starting vision of 20/50 or worse. Nevertheless the 3 drugs mentioned above led to similar average improvement whenever starting vision was 20/40 to 20/32.

MED

The study was conducted by the Diabetic Retinopathy Clinical Research Network, funded by the U.S. National Eye Institute (NEI), and was published online Wednesday in the New England Journal of Medicine.

According to the NEI, roughly 750,000 Americans currently suffer from diabetic macular edema. This condition can affect people with a type of diabetes-related eye disease, which is called diabetic retinopathy. Actually the DME is among the most common reasons for visual loss that may affect the 7.7 million Americans who are suffering from diabetic retinopathy. This condition usually occurs whenever abnormal blood vessels in the retina start leaking into the central area of the retina thus causing distorted vision.

“The results certainly seem to suggest here that if you have 20/50 vision or worse, you would certainly consider Eylea as the preferred drug,”

Dr. John A. Wells, a retina specialist in West Columbia, S.C., who was the chairman of the study, explained.

Among patients with the baddest vision, 67 % in the Eylea group noticed an improvement of about 15 letters, or three lines on an eye chart, which is undoubtedly a meaningful progress. Only 50 % of the ones treated with Lucentis, along with 41% treated with Avastin, admitted to have gained that much vision.

Moreover the study also found that patients getting Eylea eventually ended up needing fewer injections and less backup treatments, like lasers.

Dr. Frederick L. Ferris III, the clinical director of the NEI and also a study co-author, explained that their findings proved all the studied drugs to be effective, but nevertheless these public results can aid guide the medical care in a manner that’s based on evidence as well.

As far as Medicare allowable charges are concerned, the costs of each drug per injection dose used in the study were $1,960 for Eylea, $70 for Avastin, and $1200 for Lucentis. But keep in mind the fact that during this one year-long study, the participants on Avastin and Lucentis received about 10 injections, while the ones on Eylea received only 9.

 

 

Filed Under: Health Tagged With: aflibercept, Avastin, bevacizumab, Diabetes-related vision loss, diabetic macular edema, DME, Eylea, John A. Wells, Lucentis, National Eye Institute, NEI, ranibizumab

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Recent Articles

Albert Einstein in group photo

Einstein’s Travel Diaries Reveal His Lesser Known Racist Side

June 14, 2018 By John Birks

Baobab tree in Tanzania

Southern Africa’s Iconic Baobab Trees Facing Massive Die-Off

June 11, 2018 By John Birks

UFO 'Self Parking' Sign

Researcher Accuses NASA of Massive Alien Cover-Up

March 5, 2018 By John Birks

Elon Musk's flying Tesla roadster

NASA Warns Elon Musk’s Flying Tesla Roadster May Contaminate Mars

February 28, 2018 By John Birks

Windows 10 home screen

Microsoft Working on Making Windows Password-Free

February 12, 2018 By John Birks

Ice Cubes

Scientists Discover Fourth State of Water: Superionic Ice

February 10, 2018 By John Birks

Head of a northern gannet

Forever Alone Nigel the Gannet Found Dead near Fake Partner

February 3, 2018 By John Birks

Globular Star Cluster

Scientists Find Surprise Black Hole in Globular Star Cluster

January 20, 2018 By John Birks

The Amazon Echo Dot

America’s Smart Speaker Market Jumps to 39 Million Users

January 15, 2018 By John Birks

Pink plasma ball

CES 2018: Intel Presents Out-of-This-World Quantum Computer

January 10, 2018 By John Birks

Teen using her iPad

Major Apple Investors Urge Company to Do More About iPhone Addiction

January 8, 2018 By John Birks

Russian spacecraft

Out-of-Control Chinese Space Station Hurling Toward Earth

January 5, 2018 By John Birks

wanning moon seen on the evening sky in between trees

Scientists Thrilled about Trump’s Initiative to Send Explorers Back to the Moon

December 31, 2017 By John Birks

Two iPhone 7 models on table

Apple Confirms Slower-iPhone Conspiracy Theory

December 22, 2017 By John Birks

Categories

  • Business & Economy
  • Capital & Retail Sector
  • Health
  • IT & Diversified Sector
  • National & Global News
  • Tech & Science

Copyright © 2021 MirrorDaily.com

About · Privacy Policy · Terms of Use · Contact